| Medical Mutual | Ryplazim® (plasminogen, human-tvmh) (Intravenous) | 2025-05-05 |
| Medical Mutual | Vyondys 53® (golodirsen) (Intravenous) | 2025-05-05 |
| Aetna | Inflammatory Bowel Disease: Serologic Markers and Pharmacogenomic and Metabolic Assessment of Thiopurine Therapy | 2025-05-01 |
| UHC Medicare Advantage | Electrical Stimulators – Medicare Advantage Medical Policy | 2025-05-01 |
| UHC Medicare Advantage | Experimental Procedures and Items, Investigational Devices, and Clinical Trials – Medicare Advantage Medical Policy | 2025-05-01 |
| UHC Medicare Advantage | Osteopathic Manipulations (OMT) – Medicare Advantage Medical Policy | 2025-05-01 |
| UHC Medicare Advantage | Positron Emission Tomography (PET) Scan for Myocardial Imaging - Medicare Advantage Medical Policy | 2025-05-01 |
| UHC UMR Medical and Drug | Crysvita® (Burosumab-Twza) – Commercial Medical Benefit Drug Policy | 2025-05-01 |
| UHC UMR Medical and Drug | Parsabiv® (Etelcalcetide) – Commercial Medical Benefit Drug Policy | 2025-05-01 |
| UHC UMR Medical and Drug | Tzield® (Teplizumab-Mzwv) – Commercial Medical Benefit Drug Policy | 2025-05-01 |